HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study.

AbstractOBJECTIVE:
To evaluate the relationship between the use of zolpidem and subsequent cancer risk in Taiwanese patients.
METHODS:
We used data from the National Health Insurance system of Taiwan to investigate whether use of zolpidem was related to cancer risk. For the study cohort, we identified 14,950 patients who had received a first prescription for zolpidem from January 1, 1998, through December 31, 2000. For each zolpidem user, we selected randomly 4 comparison patients without a history of using zolpidem who were frequency-matched by sex, age, and year of the index date. Incidence rates of all cancers and selected site-specific cancers were measured by the end of 2009, and related hazard ratios (HRs) and 95% confidence intervals (CIs) of the cancer were measured as well.
RESULTS:
The risk of developing any cancer was greater in patients using zolpidem than in nonusers (HR, 1.68; 95% CI, 1.55-1.82). The stratified analysis showed that the overall HR for high-dosage zolpidem (≥300 mg/y) was 2.38. The site-specific cancer risk was the highest for oral cancer (HR, 2.36; 95% CI, 1.57-3.56), followed by kidney cancer, esophageal cancer, breast cancer, liver cancer, lung cancer, and bladder cancer (HR, 1.60; 95% CI, 1.06-2.41). Men were at higher risk than women.
CONCLUSION:
This population-based study revealed some unexpected findings, suggesting that the use of zolpidem may be associated with an increased risk of subsequent cancer. Further large-scale and in-depth investigations in this area are warranted.
AuthorsChia-Hung Kao, Li-Min Sun, Ji-An Liang, Shih-Ni Chang, Fung-Chang Sung, Chih-Hsin Muo
JournalMayo Clinic proceedings (Mayo Clin Proc) Vol. 87 Issue 5 Pg. 430-6 (May 2012) ISSN: 1942-5546 [Electronic] England
PMID22560522 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Hypnotics and Sedatives
  • Pyridines
  • Zolpidem
Topics
  • Adult
  • Breast Neoplasms (chemically induced, epidemiology)
  • Cohort Studies
  • Confidence Intervals
  • Esophageal Neoplasms (chemically induced, epidemiology)
  • Female
  • Humans
  • Hypnotics and Sedatives (adverse effects, therapeutic use)
  • Liver Neoplasms (chemically induced, epidemiology)
  • Lung Neoplasms (chemically induced, epidemiology)
  • Male
  • Middle Aged
  • Mouth Neoplasms (chemically induced, epidemiology)
  • Neoplasms (chemically induced, epidemiology)
  • Odds Ratio
  • Population Surveillance
  • Pyridines (adverse effects, therapeutic use)
  • Risk Factors
  • Sex Distribution
  • Sleep Initiation and Maintenance Disorders (drug therapy)
  • Taiwan (epidemiology)
  • Urinary Bladder Neoplasms (chemistry, epidemiology)
  • Young Adult
  • Zolpidem

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: